Carlsbad, CA, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepted for poster presentation at ACG’s 2024 Annual Scientific Meeting being held October 25-30, 2024 in Philadelphia, PA.
The American College of Gastroenterology (ACG) is a recognized leader in educating GI professionals and the general public about digestive disorders. For more information about the ACG Annual Meeting, please visit the conference website.
About Palisade Bio
Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.48 |
| Daily Change: | 0.05 3.50 |
| Daily Volume: | 438,571 |
| Market Cap: | US$4.100M |
January 22, 2025 January 16, 2025 December 13, 2024 November 21, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
